In postmenopausal women with severe osteoporosis in the VERO trial, the greater fracture risk reduction with teriparatide versus risedronate did not differ significantly across psychotropic drug or PPI use categories in a post-hoc analysis.
In plain wordsIn postmenopausal women with severe osteoporosis, teriparatide's greater fracture risk reduction than risedronate did not differ significantly by use of psychotropic drugs or PPIs.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- No significant changeDifference in teriparatide versus risedronate fracture risk reduction across medication categories
- Study
n = 1,360
- Comparator
- Risedronate
- Outcome group
- Bone and joint · Musculoskeletal
Source sentences
For all fracture endpoints, the greater risk reduction of teriparatide versus risedronate did not significantly differ within the categories of psychotropic drugs and PPIs.
2 context sentences(design, population, supporting numbers)
A total of 1360 postmenopausal women with at least 2 moderate or 1 severe VFx and bone mineral density T-score ≤-1.50 were randomized to subcutaneous daily teriparatide (20μg) or oral weekly risedronate (35mg) in a double-blind, double-dummy, 2-year trial.
In thispost-hoc analysis, multivariable log-binomial and Cox proportional hazards regression models were used to estimate adjusted risk ratios (RR) or hazard ratios (HR) for the exposure to these concomitant medications with the occurrence of incident fractures.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).